CLINIQUES UNIVERSITAIRES SAINT-LUC ASBL

Their core work

Cliniques Universitaires Saint-Luc is a major Belgian university hospital in Brussels, serving as a clinical research site for European multi-center trials in oncology, pain medicine, and immune-mediated diseases. They contribute patient cohorts, clinical expertise, and biological sample collection to large-scale translational research projects. Their strength lies in bridging bedside patient care with structured clinical data generation — particularly in immunotherapy, chronic pain management, and rare disease characterization.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2017), Saint-Luc focused on cardiac dysfunction (beta3-adrenergic receptor trials), severe sepsis with stem cell therapy, and gut microbiome research — a broad clinical base without a dominant theme. From 2018 onward, two clear pillars emerged: chronic pain research (with deep phenotyping and pharmacological modeling) and cancer immunotherapy (immunoprofiling, mRNA vaccines, combination immunotherapy). This shift reflects a hospital moving from general clinical trial participation toward becoming a specialized site for precision medicine in pain and oncology.

Saint-Luc is consolidating around precision oncology (immunoprofiling, mRNA vaccines) and quantitative pain management — expect future proposals in personalized cancer treatment and digital pain assessment tools.

How they like to work

Saint-Luc never coordinates H2020 projects — they consistently join as a clinical partner or third-party site in large multi-center consortia. With 242 unique partners across 22 countries, they maintain a wide European network rather than a tight cluster of repeat collaborators. This makes them a reliable, low-overhead clinical site: they bring patients, samples, and clinical data without seeking project leadership overhead.

Extensively networked across 22 countries with 242 unique consortium partners, reflecting their role as a clinical site recruited into large multi-center trials. No geographic concentration — their partnerships span Western and Eastern Europe broadly.

What sets them apart

As a top-tier Belgian university hospital linked to UCLouvain, Saint-Luc offers something many research institutes cannot: direct access to diverse patient populations within a single integrated clinical environment. Their dual focus on chronic pain and cancer immunotherapy makes them particularly valuable for projects needing clinical validation sites that can handle both biomarker collection and patient-reported outcome measures. For consortium builders, they are a proven, experienced clinical partner who will deliver patient data reliably without competing for coordination roles.

Highlights from their portfolio

• SEPCELL
  Their highest-funded project (EUR 534,375), testing allogeneic stem cell therapy for severe sepsis — an ambitious regenerative medicine approach to a critical care problem.
• TIGER
  Their most recent project (2021-2025), a proof-of-concept for therapeutic mRNA cancer vaccines using TriMix technology against HPV-related cancers — positioning them at the frontier of mRNA therapeutics.
• IMI-PainCare
  Part of the Innovative Medicines Initiative, this project anchors their pain research identity with deep phenotyping, biomarker discovery, and patient stratification across multiple pain conditions.